Abstract

The SciLifeLab Drug Discovery and Development (DDD) platform was established in 2014 with earmarked funds within SciLifeLab to establish a national platform to support academic research projects with a potential to result in new therapeutics. DDD supports projects with the potential to result in new therapeutics, enabling life science research that would otherwise not be possible. It offers industry standard infrastructure, expertise, and strategic support to drug discovery projects for progression towards pre-clinical proof-of concept and a strategy for further development. The platform funding reflects the government´s ambition that Sweden should remain a leading life science nation. Major specific objectives for DDD are: • To increase reproducibility of academic life science data by providing an industry standard infrastructure tailor-made for drug discovery research • To provide expert knowledge and training in drug discovery to the academia • Make tomorrow´s drug discovery technologies available to Swedishresearchers SciLifeLab DDD consist of 10 units distributed at 6 Swedish Universities. DDD (Royal Institute of KTH, Uppsala University, Stockholm University, Karolinska Institutet, University of Gothenburg and Lund University) DDD works with different modalities such as small molecule, antibodies and oligonucleotides